Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico

Detalhes bibliográficos
Autor(a) principal: Cordeiro, Alexandra
Data de Publicação: 2009
Outros Autores: Lermann, Rita, Ambrósio, Paula, Nogueira, Isabel, Serrano, Fátima
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/22011
Resumo: Background and aims: Antiphospholipid antibodies (APLAs) have been associated with pregnancy loss and other obstetric complications, such as pre-eclampsia, fetal growth restriction and preterm delivery. Systemic lupus erythematosus (SLE) patients frequently present APLAs and secondary antiphospholipid syndrome. The purpose of this work is to evaluate pregnancy outcome in SLE patients with and without APLAs. Material and Methods: Retrospective analysis of 136 gestations in women with SLE diagnosis previous to pregnancy that underwent surveillance in our maternity from 1993 to 2007. Patients with and without APLAs were considered separately. Maternal age, obstetric history, SLE activity and nephropathy, present pregnancy evolution, gestational age at delivery, mode of delivery, birth weight and hypertensive complications were identified. Results: 28% (38) of pregnant SLE patients had APLAs. From these patients, 28.9.8% had past history of second and/or third trimester fetal losses, against 6.12% in patients without APLAs (p<0.05). Evaluation of present pregnancy outcome revealed, for APLAs positive patients, a significant higher rate of non-successful pregnancy (8.1% vs; 2.1%, p<0.05). Analysis of mean birth weight and intrauterine growth restriction rates revealed no signifi-cant differences related to APLAs presence. Mean gestational age at delivery was 36.9 weeks for both groups with identical preterm delivery rates. Cesarean section was the mode of delivery for 47% and 44.1% of the patients, in APL patients and others, respectively. Conclusions: SLE patients with APLAs had more spontaneous abortions and worse obstetric history, with no other significant differences in perinatal and obstetric outcome.
id RCAP_cf1b0dc6354d50cd45c29a439a61fd80
oai_identifier_str oai:run.unl.pt:10362/22011
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognósticoPregnancy and antiphospholipid antibodies in systemic lupus erithematosus patients: an outcome evaluationLúpus Eritematoso SistémicoGravidezAnticorpos AntifosfolípidosBackground and aims: Antiphospholipid antibodies (APLAs) have been associated with pregnancy loss and other obstetric complications, such as pre-eclampsia, fetal growth restriction and preterm delivery. Systemic lupus erythematosus (SLE) patients frequently present APLAs and secondary antiphospholipid syndrome. The purpose of this work is to evaluate pregnancy outcome in SLE patients with and without APLAs. Material and Methods: Retrospective analysis of 136 gestations in women with SLE diagnosis previous to pregnancy that underwent surveillance in our maternity from 1993 to 2007. Patients with and without APLAs were considered separately. Maternal age, obstetric history, SLE activity and nephropathy, present pregnancy evolution, gestational age at delivery, mode of delivery, birth weight and hypertensive complications were identified. Results: 28% (38) of pregnant SLE patients had APLAs. From these patients, 28.9.8% had past history of second and/or third trimester fetal losses, against 6.12% in patients without APLAs (p<0.05). Evaluation of present pregnancy outcome revealed, for APLAs positive patients, a significant higher rate of non-successful pregnancy (8.1% vs; 2.1%, p<0.05). Analysis of mean birth weight and intrauterine growth restriction rates revealed no signifi-cant differences related to APLAs presence. Mean gestational age at delivery was 36.9 weeks for both groups with identical preterm delivery rates. Cesarean section was the mode of delivery for 47% and 44.1% of the patients, in APL patients and others, respectively. Conclusions: SLE patients with APLAs had more spontaneous abortions and worse obstetric history, with no other significant differences in perinatal and obstetric outcome.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNCordeiro, AlexandraLermann, RitaAmbrósio, PaulaNogueira, IsabelSerrano, Fátima2017-07-17T22:00:45Z2009-072009-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article6application/pdfhttp://hdl.handle.net/10362/22011por0303-464XPURE: 300033info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:09:15Zoai:run.unl.pt:10362/22011Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:27:05.776308Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
Pregnancy and antiphospholipid antibodies in systemic lupus erithematosus patients: an outcome evaluation
title Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
spellingShingle Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
Cordeiro, Alexandra
Lúpus Eritematoso Sistémico
Gravidez
Anticorpos Antifosfolípidos
title_short Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
title_full Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
title_fullStr Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
title_full_unstemmed Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
title_sort Gravidez e anticorpos antifosfolípidos em doentes com lúpus eritematoso sistémico: uma avaliação do prognóstico
author Cordeiro, Alexandra
author_facet Cordeiro, Alexandra
Lermann, Rita
Ambrósio, Paula
Nogueira, Isabel
Serrano, Fátima
author_role author
author2 Lermann, Rita
Ambrósio, Paula
Nogueira, Isabel
Serrano, Fátima
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Cordeiro, Alexandra
Lermann, Rita
Ambrósio, Paula
Nogueira, Isabel
Serrano, Fátima
dc.subject.por.fl_str_mv Lúpus Eritematoso Sistémico
Gravidez
Anticorpos Antifosfolípidos
topic Lúpus Eritematoso Sistémico
Gravidez
Anticorpos Antifosfolípidos
description Background and aims: Antiphospholipid antibodies (APLAs) have been associated with pregnancy loss and other obstetric complications, such as pre-eclampsia, fetal growth restriction and preterm delivery. Systemic lupus erythematosus (SLE) patients frequently present APLAs and secondary antiphospholipid syndrome. The purpose of this work is to evaluate pregnancy outcome in SLE patients with and without APLAs. Material and Methods: Retrospective analysis of 136 gestations in women with SLE diagnosis previous to pregnancy that underwent surveillance in our maternity from 1993 to 2007. Patients with and without APLAs were considered separately. Maternal age, obstetric history, SLE activity and nephropathy, present pregnancy evolution, gestational age at delivery, mode of delivery, birth weight and hypertensive complications were identified. Results: 28% (38) of pregnant SLE patients had APLAs. From these patients, 28.9.8% had past history of second and/or third trimester fetal losses, against 6.12% in patients without APLAs (p<0.05). Evaluation of present pregnancy outcome revealed, for APLAs positive patients, a significant higher rate of non-successful pregnancy (8.1% vs; 2.1%, p<0.05). Analysis of mean birth weight and intrauterine growth restriction rates revealed no signifi-cant differences related to APLAs presence. Mean gestational age at delivery was 36.9 weeks for both groups with identical preterm delivery rates. Cesarean section was the mode of delivery for 47% and 44.1% of the patients, in APL patients and others, respectively. Conclusions: SLE patients with APLAs had more spontaneous abortions and worse obstetric history, with no other significant differences in perinatal and obstetric outcome.
publishDate 2009
dc.date.none.fl_str_mv 2009-07
2009-07-01T00:00:00Z
2017-07-17T22:00:45Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/22011
url http://hdl.handle.net/10362/22011
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 0303-464X
PURE: 300033
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137899905548288